GSK-CureVac's 2nd Covid vax shows better immune response


Berlin, Aug 17 (IANS): The second mRNA Covid-19 Vaccine developed by German biopharmaceutical company CureVac and its British partner GlaxoSmithKline (GSK) has demonstrated improved immune response and protection than its first vaccine, according to a new study.

The animal-based study, yet to be peer-reviewed and posted on pre-print server bioRxiv, shows that CV2CoV has higher neutralising capacity against a range of variants, including the Beta, Delta and Lambda variant and the original virus strain, the company said in a statement on Monday.

CureVac's first mRNA-based Covid vaccine CVnCoV, showed efficacy of just 47 per cent, the lowest reported so far from any Covid-19 vaccine maker.

The new study assessed cynomolgus macaques vaccinated with 12 microgram of either the first or second-generation vaccine candidate.

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.

When tested against the original SARS-CoV-2 virus, the animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages, the company said.

"In this animal model, CV2CoV is shown to induce broad antibody and cellular immune responses very similar to the breadth of the immune responses observed after infection with SARS-CoV-2," said Dr. Igor Splawski, Chief Scientific Officer of CureVac.

The companies aim to roll out CV2CoV's Phase 1 clinical trial in Q4 2021.

The mRNA technology was a "strategic priority", said Rino Rappuoli, head of vaccines research and development at GSK

"The strong immune response and protection in pre-clinical testing of this second-generation mRNA backbone are very encouraging and represent an important milestone," he added.

Meanwhile, CureVac faced heavy losses in the second quarter. Its operating loss was 147.8m euros for the three months ending June 30, compared with a loss of 3.2m euros in the second quarter of 2020.

Revenue was 22.4m euros, down 35 per cent from a year ago.

 

  

Top Stories


Leave a Comment

Title: GSK-CureVac's 2nd Covid vax shows better immune response



You have 2000 characters left.

Disclaimer:

Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. Daijiworld.com will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will Daijiworld.com be held responsible.


Security Validation

Enter the characters in the image